Patents by Inventor Neil Castle

Neil Castle has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230365575
    Abstract: Disclosed are compounds according to Formula (I) or (II), and pharmaceutical compositions comprising them. Also disclosed are therapeutic methods, e.g., of treating kidney diseases, using the compounds of Formula (I) or (II).
    Type: Application
    Filed: February 1, 2023
    Publication date: November 16, 2023
    Inventors: Matthew H. Daniels, Maolin Yu, Jean-Christophe P. Harmange, Thomas T. Tibbitts, Mark W. Ledeboer, Neil A. Castle, Goran Malojcic
  • Patent number: 11623930
    Abstract: Disclosed are compounds according to Formula (I) or (II), and pharmaceutical compositions comprising them. Also disclosed are therapeutic methods, e.g., of treating kidney diseases, using the compounds of Formula (I) or (II).
    Type: Grant
    Filed: March 5, 2019
    Date of Patent: April 11, 2023
    Assignee: Goldfinch Bio, Inc.
    Inventors: Matthew H. Daniels, Maolin Yu, Jean-Christophe P. Harmange, Thomas T. Tibbitts, Mark W. Ledeboer, Neil A. Castle, Goran Malojcic
  • Publication number: 20210087200
    Abstract: Disclosed are compounds according to Formula (I) or (II), and pharmaceutical compositions comprising them. Also disclosed are therapeutic methods, e.g., of treating kidney diseases, using the compounds of Formula (I) or (II).
    Type: Application
    Filed: March 5, 2019
    Publication date: March 25, 2021
    Inventors: Matthew H. Daniels, Maolin Yu, Jean-Christophe P. Harmange, Thomas T. Tibbitts, Mark W. Ledeboer, Neil A. Castle, Goran Malojcic
  • Publication number: 20100056637
    Abstract: The present invention provides methods of treating or preventing asthma or an inflammatory disease. In one embodiment, the invention provides compounds and formulations for the treatment of asthma or an inflammatory disease.
    Type: Application
    Filed: September 18, 2009
    Publication date: March 4, 2010
    Applicant: Icagen, Inc.
    Inventors: Neil A. Castle, Gregory C. Rigdon, Douglas S. Krafte, Jeffrey L. Krajewski
  • Publication number: 20090036538
    Abstract: The use of novel inhibitors of potassium flux is disclosed for the treatment of inflammatory processes, such as multiple sclerosis, insulin-dependent (type I) diabetes mellitus, rheumatoid arthritis, peripheral neuritis and pulmonary hypertension. The compounds are also of use in treating and preventing stroke. These inhibitors have a high specificity for the IK1 channel and greater stability relative to non-fluorine substituted homologues.
    Type: Application
    Filed: September 19, 2008
    Publication date: February 5, 2009
    Applicant: Icagen, Inc.
    Inventors: Neil A. Castle, Gregory C. Rigdon, Douglas S. Krafte
  • Publication number: 20070185209
    Abstract: The use of novel inhibitors of potassium flux is disclosed for the treatment of inflammatory processes, such as multiple sclerosis, insulin-dependent (type I) diabetes mellitus, rheumatoid arthritis, peripheral neuritis and pulmonary hypertension. The compounds are also of use in treating and preventing stroke. These inhibitors have a high specificity for the IK1 channel and greater stability relative to non-fluorine substituted homologues.
    Type: Application
    Filed: December 20, 2006
    Publication date: August 9, 2007
    Applicant: Icagen, Inc.
    Inventors: Neil Castle, Gregory Rigdon, Douglas Krafte
  • Publication number: 20030199578
    Abstract: The present invention relates to compounds and their ability to act as potassium channel openers.
    Type: Application
    Filed: April 19, 2002
    Publication date: October 23, 2003
    Inventors: Sean C. Turner, Neil A. Castle, William A. Carroll, Tammie K. White
  • Patent number: 6395730
    Abstract: Certain thiazolidinone and metathiazanone compounds, as described, are useful as potassium channel inhibitors and are especially useful for the treatment of cardiac arrhythmias and other diseases, conditions and disorders.
    Type: Grant
    Filed: October 13, 2000
    Date of Patent: May 28, 2002
    Assignees: Icagen, Inc., Eli Lilly and Company
    Inventors: Michael F. Gross, Neil A. Castle, Jose S. Mendoza
  • Patent number: 6333337
    Abstract: Compounds useful as potassium channel inhibitors and especially useful for the treatment of cardiac arrhythmias and cell proliferative disorders are described.
    Type: Grant
    Filed: January 13, 1999
    Date of Patent: December 25, 2001
    Assignee: ICAgen, Inc.
    Inventors: Michael F. Gross, Neil A. Castle
  • Patent number: 6174908
    Abstract: Certain thiazolidinone and metathiazanone compounds, as described, are useful as potassium channel inhibitors and are especially useful for the treatment of cardiac arrhythmias and other diseases, conditions and disorders.
    Type: Grant
    Filed: May 1, 1999
    Date of Patent: January 16, 2001
    Assignees: ICAGen, Inc., Eli Lilly & Company Lilly Corporate Center
    Inventors: Michael F. Gross, Neil A. Castle, Jose S. Mendoza
  • Patent number: D626873
    Type: Grant
    Filed: August 6, 2009
    Date of Patent: November 9, 2010
    Inventors: Neil Castle, Neil Diaz, Paul Castle
  • Patent number: D654388
    Type: Grant
    Filed: November 8, 2010
    Date of Patent: February 21, 2012
    Inventors: Neil Castle, Neil Diaz, Paul Castle
  • Patent number: D684493
    Type: Grant
    Filed: February 21, 2012
    Date of Patent: June 18, 2013
    Inventors: Neil Castle, Neil Diaz, Paul Castle